Novartis
This article was originally published in The Tan Sheet
Executive Summary
Company's acquisition of 20% of Roche voting stock for $2.8 bil. is not expected to impact its nutritionals businesses, firm says. Calling move a long-term financial investment primarily involving its pharmaceutical operations, Novartis says Roche's position in bulk vitamin industry would not likely affect ReSource Wellness line or functional food strategy. Novartis is reviewing functional foods options after halting distribution of Aviva line in foreign markets due to lower-than-expected consumer reception. CFO Raymond Breu referred to firm's nutrition businesses as "farther away" from its core pharmaceutical goals at J.P. Morgan conference in late April (1"The Tan Sheet" May 7, p. 6)
You may also be interested in...
Novartis OTCs Fit Well With Pharma Core - CFO
Novartis' nutritional and eye care businesses are seen as "farther away" from the company's core pharmaceutical focus going forward, CFO Raymund Breu told a J.P. Morgan CEO conference on building shareholder value April 26.
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands